Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study

Overview

Journal Cancer Control

Specialty Oncology

Date 2023 Sep 19

PMID 37724508

Authors

Ronen Brenner

Shlomit Amar-Farkash

Avital Klein-Brill

Keren Rosenberg-Katz

Dvir Aran

Affiliations

Soon will be listed here.

Abstract

Background: FOLFOX (leucovorin calcium [folinic acid], fluorouracil, and oxaliplatin) combined with or without anti-VEGF therapy represents one of the primary first-line treatment options for metastatic colorectal carcinoma (mCRC). However, there is limited comparative data on the impact of anti-VEGF therapy on treatment effectiveness, survival outcomes, and tumor location.

Methods: This retrospective, comparative study utilized data from the AIM Cancer Care Quality Program and commercially insured patients treated at medical oncology clinics in the US. We analyzed 1652 mCRC patients who received FOLFOX, of which 1015 (61.4%) were also treated with anti-VEGF therapy (VEGF cohort).

Results: Patients in the VEGF cohort exhibited a higher frequency of lung (33% vs 23%; < .001) and liver metastases (74% vs 62%; < .001), underwent fewer liver surgeries prior to treatment (1.2% vs 3.6%; = .002), and had a higher proportion of right-sided tumors (27% vs 18%; = .001). Adjusted analysis revealed no significant difference in overall survival (OS) between patients treated with and without anti-VEGF (median survival: 25.4 vs 26.0 months; = .4). FOLFOX-only treated patients experienced higher rates of post-treatment hospitalizations (22% vs 15%; < .001). Notably, left-sided tumors treated with anti-VEGF showed a trend toward decreased OS (median survival: 26.8 vs 33 months; = .09).

Conclusion: Our real-world data analysis suggests that the addition of anti-VEGF to FOLFOX offers limited and short-lived benefits in the context of mCRC and may provide differential survival benefit based on tumor sidedness.

References

Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P . Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016; 3(2):211-219. DOI: 10.1001/jamaoncol.2016.4227. View

Jemielita T, Li X, Piperdi B, Zhou W, Burke T, Chen C . Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data. JCO Clin Cancer Inform. 2021; 5:56-65. DOI: 10.1200/CCI.20.00099. View

Grothey A, Sargent D, Goldberg R, Schmoll H . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22(7):1209-14. DOI: 10.1200/JCO.2004.11.037. View

Stathopoulos G, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J . Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology. 2010; 78(5-6):376-81. DOI: 10.1159/000320520. View

Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini M . FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol. 2016; 27(5):843-9. DOI: 10.1093/annonc/mdw052. View

Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A . Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011; 16(4):432-44. PMC: 3228115. DOI: 10.1634/theoncologist.2010-0271. View

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W . Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015; 107(3). PMC: 4565528. DOI: 10.1093/jnci/dju427. View

Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A . Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol. 2015; 26(6):1201-1207. DOI: 10.1093/annonc/mdv130. View

Chang C, Meng L, Li X, Cheng K, Yi C, Peng B . A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Cancer Control. 2022; 29:10732748221141233. PMC: 9703471. DOI: 10.1177/10732748221141233. View

10.

Wong H, Lee B, Field K, Lomax A, Tacey M, Shapiro J . Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2016; 15(2):e9-e15. DOI: 10.1016/j.clcc.2016.02.007. View

11.

Dai D, Wang Y, Zhu L, Jin H, Wang X . Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis. PeerJ. 2020; 8:e9149. PMC: 7271887. DOI: 10.7717/peerj.9149. View

12.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. View

13.

Kern D, Barron J, Wu B, Ganetsky A, Willey V, Quimbo R . A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. Pragmat Obs Res. 2017; 8:149-155. PMC: 5584892. DOI: 10.2147/POR.S140579. View

14.

Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson E, Aran D . Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Netw Open. 2022; 5(6):e2216199. PMC: 9178436. DOI: 10.1001/jamanetworkopen.2022.16199. View

15.

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R . Validation of diagnosis codes to identify side of colon in an electronic health record registry. BMC Med Res Methodol. 2019; 19(1):177. PMC: 6700780. DOI: 10.1186/s12874-019-0824-7. View

16.

Fuchs C, Marshall J, Barrueco J . Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008; 26(4):689-90. DOI: 10.1200/JCO.2007.15.5390. View

17.

Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12):2013-9. DOI: 10.1200/JCO.2007.14.9930. View

18.

Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

19.

Arnold D, Lueza B, Douillard J, Peeters M, Lenz H, Venook A . Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017; 28(8):1713-1729. PMC: 6246616. DOI: 10.1093/annonc/mdx175. View

20.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View